MGNX News and Press, MacroGenics Inc. From 11/04/20

ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinica...

ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will r...

Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial. MacroGenics reports positive data for flotetuzumab immunotherapy. Merck provides updated positive data for Keytruda in lung cancer. For further details see: Jazz Announces Topline Data, And Other News:...

MacroGenics (MGNX) publishes a report on the role of Flotetuzumab (also known as MGD006) in the immunotherapy of TP53-positive acute myeloid leukemia ((AML)) in a journal of the American Society of Hematology.Flotetuzumab is an investigational, clinical-stage bispecific DA...

ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of...

The first patient has been dosed in a China-based Phase 2/3 study, MAHOGANY, evaluating Zai Lab's (ZLAB) margetuximab, combined with a checkpoint inhibitor, with or without chemo, for the first-line treatment of HER2-positive gastric cancer or gastroesophageal junction cancer.The PD-1 inhibit...

Leap Therapeutics initiates Phase 2a trial for DKN-01. MacroGenics reports progress on MGA012 development. BridgeBio Pharma starts Phase 2 encaleret trial. For further details see: Leap Therapeutics Initiates Trial, And Other News: The Good, Bad And Ugly Of Biopharma

MacroGenics ([[MGNX]]) announces the development of MGC018, an investigational antibody-drug conjugate ((ADC)) targeting B7-H3 for the treatment of solid tumors in a journal of the American Association for Cancer Research. Preclinical studies showed that MGC018 mediated specific in ...

Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), ...

MacroGenics (MGNX) announces encouraging preliminary data from a Phase 1/2 clinical trial evaluating flotetuzumab in acute myeloid leukemia ((AML)) patients. The results were just published in the journal Blood.In a subset of patients high poor prognoses and high unmet medical needs, the comp...